As the European Medicines Agency (EMA) risk assessment deadline takes hold, Ellutia's total nitrosamines pre-screening solution offers the pharmaceutical industry a simple, accurate and reliable test. This delivers a clear pass/fail result for apparent total nitrosamine content (ATNC) in minutes, allowing samples to be immediately cleared for processing or sent for further testing. From April 2020, all marketing authorisation holders of medicines containing chemically synthesised active pharmaceutical ingredients (APIs) must conduct a risk assessment to evaluate the possibility of nitrosamines being present.
展开▼
